0.00Open0.00Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover250.72%IV-177.78%PremiumDec 20, 2024Expiry Date19.20Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8739Delta0.0293Gamma0.55Leverage Ratio-0.0253Theta-0.0138Rho-0.48Eff Leverage0.0062Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet